Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia YELLOW III supports aggressive lipid lowering to reduce plaque progression CLEAR Outcomes shows 13% reduction in CV events with bempedoic acid Olpasiran reduces Lp(a) irrespective of baseline Lp(a)AT-TARGET-IT: Real world data show high adherence to PCSK9 inhibitors Genetic variants in PCSK9 gene not linked to heart failure

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

Combination therapy in familial hypercholesterolaemia: what can we gain from novel agents?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Professor John Chapman

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis Coronary artery calcium in familial hypercholesterolaemia CLEAR OUTCOMES: Topline data show bempedoic acid reduces cardiovascular events PCSK9 inhibitors: effects beyond LDL cholesterol lowering

Most viewed

Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis

Hot Topics

17th Virtual Closed Scientific Expert Meeting of the Editorial Board

What's new in lipoprotein(a) therapeutics?
Dr Michael Koren overviews the latest data with the siRNA olpasiran, including the OCEAN(a) trial.

Watch now

Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

View all presentations from the 17th Closed Scientific Expert Meeting »

From the Editors

Lipoprotein(a) and atrial fibrillation – Is there a link?

John chapman & Henry Ginsberg Profs. John Chapman and Henry Ginsberg discuss new data implicating Lp(a) as a potential causal mediator of atrial fibrillation.